skip to Main Content

About PILA PHARMA

PILA PHARMA is a publicly held clinical stage pharmaceutical company based in Malmö, Sweden.
The company is developing a TRPV1 antagonist, XEN-D0501, as a novel type of oral anti-diabetic agent.

XEN-D0501 is a synthetic small molecule that was in-licensed in 2016.
Prior to in-licensing, XEN-D0501 had been found to have a good safety profile in other (non-diabetic) patient groups.

PILA PHARMA has to date completed two phase 2a clinical trials (PP-CT01 and PP-CT02), that both demonstrated that XEN-D0501 is well tolerated by people with type 2 diabetes.

Further, PP-CT02, demonstrated that XEN-D0501 (administered as 4 mg BID for 28 days) – with statistical significance versus placebo – enhance the endogenous insulin response to oral glucose.

FÅ PRESSMEDDELANDEN / GET PRESS RELEASES

PilaPharma

News

In case you missed it, our CEO’s presentation from today’s event at Aktiespararna is now online
Please, find the link to our CEOs presentation (in English) here
(02-December-2021)
Tomorrow, December 2nd at 11:30 AM, our CEO Dorte X. Gram will be presenting at Aktiespararnas “Stora Aktiedagen” in Stockholm, and, give an update on #PILA PHARMA.
It’s possible to text your questions to +46 (0)79-347 98 45 or email to event@aktiespararna.se for the moderator will handle the questions during the Q&A.
You can follow the live stream here (in English) here
(01-December-2021)
We’re delighted to announce that we have signed an agreement with ERBC (European Research Biology Center) on the conduct of our planned preclinical safety studies.
We look forward to the collaboration and, even more so, the results!
Read the full article (in English) here

Läs hela artikeln (in Swedish) här

(01-December-2021)
Pila Pharma Press releases

PILA PHARMA AB skriver avtal med den prekliniska tjänstleveranören ERBC
Läs pressmeddelandet (in Swedish) här

PILA PHARMA AB, announces ink of agreement with pre-clinical service provider ERBC
Read the press release (in English) here

(26-November-2021)
Last Sunday, Politiken, had an appendix on Diabetes and we appeared on the cover and in a nice article on p. 8-9
Read the article (in Danish) here
(23-November-2021)
We participated in the Redeye Life Science Day 2021 on Thursday last week
Please, find the link to our CEOs presentation (in English) here
(19-November-2021)
FYI our CEO increased the stock holding in PILA earlier this week. Biostock commented on the transaction
You can read it in English here
You can read it in Swedish here
(19-November-2021)
Politiken Pila Pharma
Our CEO was on the cover(again) in one of Politikens appendices on Life Sciences published last Friday
Read the article (in Danish) here
(19-November-2021)
We’re pleased to share our CEOs presentation (in Danish) last week
Thank you to Økonomisk Ugebrev Lifescience for inviting us!
Watch the video in (in Danish) here
(19-November-2021)
Pila Pharma Press releases

PILA PHARMA AB – VD Dorte X. Gram ökar sitt innehav

Läs pressmeddelandet (in Swedish) här

 

PHARMA AB – CEO Dorte X. Gram increases share holding

Read the press release (in English) here

(16-November-2021)
We’re pleased to share that our CEO Dorte X. Gram will present PILA PHARMA in Stockholm on Thursday 11 November at 16:30 at the Redeye Lifescience day 2021!
you’re invited to join! Sing up via the link here
(05-November-2021)
Biostock has written an update on us after our Q3 report release
You can read it in English here
(05-November-2021)
Save the date (10 Nov 2021): our CEO Dorte X. Gram will be presenting in Copenhagen, Denmark
you’re invited to join! Sing up via the link here
(02-November-2021)

Delårsrapport 1 juli – 30 september 2021

Läs läs rapporten PDF (in Swedish) här

(26-October-2021)
Pila Pharma Press releases

PILA PHARMA offentliggör delårsrapport för 1 juli – 30 september 2021

Läs pressmeddelandet (in Swedish) här
Läs pressmeddelandet PDF (in Swedish) här

 

PILA PHARMA publishes interim report for July 1 – September 30, 2021

Read the press release (in English) here
Read the Press release PDF (in English) here

(26-October-2021)
Pila Pharma Press releases

Nobelpris till upptäckten av PILA PHARMA:s ledande princip
Läs pressmeddelandet (in Swedish) här
Läs pressmeddelandet PDF (in Swedish) här

 

Nobel prize for the discovery of PILA PHARMA’s leading principle
Read the press release (in English) here
Read the Press release PDF (in English) here

(05-October-2021)

Yesterday, our CEO Dorte X. Gram presented our company at Aktiespararna.

Please find a link to the presentation here

(29-September-2021)
BioStock

BioStocks: “Pila Pharma takes final steps before toxicology studies”
Read the full article (in English) here

BioStocks: “Pila Pharma tar sista stegen innan toxikologiska studier”
Läs hela artikeln (in Swedish) här

(22-September-2021)
Pila Pharma Press releases

PILA PHARMA erhåller GMP-certifiering av placebo-tabletter
Läs pressmeddelandet (in Swedish) här
Läs pressmeddelandet PDF (in Swedish) här

 

PILA PHARMA recieves GMP certification of placebo tablets
Read the press release (in English) here
Read the Press release PDF (in English) here

(14-September-2021)
Life Science

Our COO, Lars Bukhave Rasmussen (and possibly som other PILAs), will be attending “The Future of Swedish & Danish Life Science” meeting in Lund, Sweden September 2nd 2021.

Read more (in English) here

(26-August-2021)
Pila Pharma Press releases

PILA PHARMA AB tecknar tillverkningsavtal om API

Läs pressmeddelandet (in Swedish) här
Läs pressmeddelandet PDF (in Swedish) here

Read the press release (in English) here
Read the Press release PDF (in English) here

(05-August-2021)
On Friday, our CEO was interviewed about PILA PHARMA ABs first week as listed company in the middle of summer and as one of the last companies in a row to list in on Nasdaq First North GM.
Thank you to MedWatch and Elizabeth Mønsted Johansen for writing about us!

Read more (in Danish) here

(23-July-2021)
Pila Pharma Press releases

Första dag för handel med teckningsoptioner, PILA TO 1, blir den 22 juli 2021

Läs pressmeddelandet här
Read the Press release PDF (in Swedish) here

(20-July-2021)

PILA PHARMA AB is off 🚀🌟
Our listing on Nasdaq was one ‘once in a life-time’ event and our CEO want to thank everybody involved in making it happen.

(15-July-2021)
Pila Pharma Press releases

I dag, den 15 juli 2021, är första handelsdag för PILA PHARMA på Nasdaq First North Growth Market

Läs pressmeddelandet här
Read the Press release PDF (in Swedish) here

(15-July-2021)

Today, at 9 am CET the PILA PHARMA team will be ringing the bell – follow us live here

(15-July-2021)

Very pleased that Nasdaq last week gave PILA PHARMA AB the final approval for the list. We look forward to ‘first trading day’ on Thursday 15 July 2021.
For your information, our ‘ticker’ ‘PILA’

Read more (in English) here

(08-July-2021)
Pila Pharma Press releases

PILA PHARMA AB (publ) nyemission blev fulltecknad – handel på Nasdaq First North Growth Market planeras starta den omkring 15 juli 2021

Läs pressmeddelandet här
Read the Press release PDF (in Swedish) here

(05-July-2021)

On 16 June, Børsen published this well-written article on PILA PHARMA AB by Kevin Grønnemann commented by Senior Equity Analyst Søren Løntoft Hansen at Sydbank. I was pleased to see, that Søren, believe ‘it can be done’! With Sørens permission, I’m pleased to share an English summary of his statements: “Even though it will not be an easy task, I think that a compound that effectively lowers blood glucose, has a good safety profile and perhaps addresses some of the co-morbidities of diabetes as cardio-vascular disease, can be made. If, on top, the compound can be marketed at lower cost, then I actually believe it has potential!”. (in Danish) here

(16 june 2021)

We are so incredibly honoured to share that the American Diabetes Association(ADA) is featuring PILA PHARMA AB in the Thought Leadership Film Series, a part of ADA’s 81st Scientific Sessions program in June 2021, starting today.

In the invitation letter, it was written: We are interested in profiling Pila’s pioneering research and development in the science surrounding TPRV1 inhibition, and how regulation of this mechanism has tremendous potential to be exploited for the treatment of diabetes. The pandemic has triggered a diabetes crisis of another sort, having multiplied the complications associated with the disease and has left diabetics more vulnerable than ever before. The pandemic has further underscored the dire need for innovative approaches that go beyond the conventional realms of the diabetes field, and therefore facilitating this is the primary focus for ADA TV this year. There is substantial pre-clinical evidence indicating a role for TPRV1 in metabolic diseases, however this novel avenue has never really been pursued despite its potential. Given that Pila Pharma is one of the few organisations that is working in this innovative space, we believe that it has the potential to make an incredibly valuable addition to this year’s series, as many in the diabetes community could learn and benefit greatly from the story behind your work.”

What at great honour – it fuels us with energy and strength to overcome all challenges ahead in order to eventually provide our new type of diabetes treatment to people with diabetes in need there off!

Thank you so much to our scientific advisors Mark Evans and Jens Juul Holst for helping our CEO explain!

Watch the video in English here

(24 june 2021)

Affärsvärlden published their IPO-analysis (in Swedish) of PILA PHARMA AB. We note that they find our premoney valuation fair here

(23 june 2021)

Thank you to Millionærklubben and Pernille Enggaard for paying attention to us and for yesterdays radio-interview of our CEO. You can listen to it here (in Danish), time 19:09 to 37:5 here

(22 june 2021)

Pitching the PILA PHARMA AB investment case live for Aktiespararna
Watch the video where we explain what PILA PHARMA is about. (in Swedish) here

(21 june 2021)

Proud to be on the cover of todays LIFE SCIENCE appedix in Politiken (in Danish)
Science for Life – makes everyday life meaningful to me!

(18 june 2021)

“PILA PHARMA vill ta ett nytt grepp om diabetes”
Biostock feature article on PILA PHARMA (in Swedish) here

(18 june 2021)

“Hon går till börsen med framtidens diabetesläkemedel”
Article on PILA PHARMA AB out now on the Swedish online magazine Realtid (in Swedish)

(20 june 2021)

”PILA PHARMA AB med den tidligere Novo Nordisk-forsker Dorte X. Gram i spidsen er nu klar til at ringe med børsklokken på det svenske Nasdaq First North Growth Market i Stockholm.”

Feature article in the life science magazine MedWatch (in Danish) here

(16 june 2021)

”PILA PHARMA rustar bolaget inför en ny fas och accelererad utvecklingsresa”
Feature article in Dagens Industri appendix Invest Talks (in Swedish) here

(15 june 2021)
Back To Top
Search